Treatment options in benign prostatic hypertrophy.
Surgery remains the first choice in patients with progressive urinary symptoms. Medical therapy--with antiandrogens, 5 alpha-reductase inhibitors, or alpha-adrenergic antagonists--may be useful in selected cases.
Stone
N N
NN
Mount Sinai School of Medicine, New York.
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy / Q000379:methods / Q000401:mortality / Q000592:standards; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome; D014563:Urodynamics / Q000187:drug effects
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D000726:Androgen Antagonists